Products Brolucizumab was approved as a solution for injection in the United States in 2019 and in many countries in 2020 (Beovu). Structure and properties Brolucizumab is a humanized monoclonal antibody fragment with a single Fv chain (single-chain antibody fragment, scFv). The molecular mass is in the range of 26 kDa. It is significantly lower … Brolucizumab
Products VEGF inhibitors are commercially available as injectables from various suppliers. The first agent in this group to be approved was pegaptanib (Macugen) in 2004, which is now off the market in many countries. Structure and properties The currently available VEGF inhibitors are therapeutic proteins (biologics). They are antibodies, antibody fragments, and fusion proteins. They … VEGF Inhibitors